Research Grade Ocrelizumab ( 奥瑞组单抗 )
- 发布日期: 2020-10-13
- 更新日期: 2025-10-24
产品详请
| 产地 |
中国
|
| 品牌 |
Chemstan
|
| 货号 |
CSD00139
|
| 保存条件 |
store at -80℃
|
| 用途 |
仅用于科研用途
|
| 应用范围 |
|
| 抗原来源 |
CHO cells
|
| CAS编号 |
637334-45-3
|
| 保质期 |
一年
|
| 抗体名 |
Ocrelizumab ( 奥瑞组单抗 )
|
| 是否单克隆 |
|
| 克隆性 |
|
| 靶点 |
MS4A1/CD20[Homo sapiens]
|
| 适应物种 |
|
| 形态 |
|
| 宿主 |
|
| 标记物 |
|
| 包装规格 |
1mg/ml
|
| 纯度 |
%
|
| 亚型 |
|
| 标识物 |
|
| 浓度 |
95%
|
| 免疫原 |
|
| 是否进口 |
否
|
货号(Catalog No.)
CSD00139
通用名INN
Ocrelizumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets the B lymphocytes that express the CD20 antigen. As a humanized molecule, ocrelizumab is expected to be less immunogenic with repeated infusions which improves the benefit-to-risk profile for patients with relapsing or progressive forms of MS.
别名(Alternative names)
2H7
靶点;物种(Specificity target name;species)
MS4A1/CD20[Homo sapiens]
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG1-nd
化学信息
分子量(MV)
145000.00 Da
CAS
637334-45-3
存储条件(Storage)
store at -80°C
Note
For research use only .